1-4 of 4
R. Jude Samulski
Close
Sort by
Journal Articles

BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression

Clinical Trials & Observations
Barbara A. Konkle, Christopher E. Walsh, Miguel A. Escobar, Neil C. Josephson, Guy Young, Annette von Drygalski, Scott W. J. McPhee, R. Jude Samulski, Ivan Bilic, Maurus de la Rosa, Birgit M. Reipert, Hanspeter Rottensteiner, Friedrich Scheiflinger, John C. Chapin, Bruce Ewenstein, Paul E. Monahan
Journal: Blood
Blood (2021) 137 (6): 763–774.
https://doi.org/10.1182/blood.2019004625
Published: 2021
Includes: Supplemental data
Journal Articles

Hemophilia B Mouse Lines Doubly Humanized for Human F9 and MHC Class II Genes Advance Specificity of Inhibitor Study

Genlin Hu, PhD, Tong Gui, PhD, Junjiang Sun, MD, Darrel W. Stafford, PhD, R. Jude Samulski, PhD, Paul E. Monahan, MD
Journal: Blood
Blood (2011) 118 (21): 200.
https://doi.org/10.1182/blood.V118.21.200.200
Published: 2011
Journal Articles

Employing Factor IX Variants to Avoid Limitations Imposed by Immune Recognition of AAV Vector in Hemophilia B Gene Therapy

Paul E. Monahan, MD, Junjiang Sun, MD, Tong Gui, PhD, David G Wichlan, Scott W McPhee, R. Jude Samulski
Journal: Blood
Blood (2011) 118 (21): 3124.
https://doi.org/10.1182/blood.V118.21.3124.3124
Published: 2011
Journal Articles

Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX

Junjiang Sun, Narine Hakobyan, Leonard A. Valentino, Brian L. Feldman, R. Jude Samulski, Paul E. Monahan
Journal: Blood
Blood (2008) 112 (12): 4532–4541.
https://doi.org/10.1182/blood-2008-01-131417
Published: 2008
Includes: Supplemental data